Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZG8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,332
Award facts
- Contract value 100% obligated
- $19,332.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $19,332.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on January 22, 2026, with an ultimate completion date of January 23, 2026, is structured as a firm fixed-price delivery order with no set-aside designation. This order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499,999,999 vehicle established to support the Department of Defense's pharmaceutical supply needs globally through multiple regional prime vendor contractors.
DMS Pharmaceutical Group has demonstrated consistent performance as a critical supplier within the federal pharmaceutical supply chain, delivering a comprehensive portfolio of branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to military healthcare facilities. The company's established capability across diverse therapeutic categories, combined with its small business status and single-award IDC contract under the PPV-G GEN V program through December 31, 2036, positions it as a key provider supporting Department of Defense medical operations worldwide. The delivery of Trikafta, a cystic fibrosis treatment, reflects the company's specialization in providing specialized pharmaceutical products essential to military healthcare requirements.
Quick answers
Who was awarded contract SPE2DR26FCZG8?
SPE2DR26FCZG8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FCZG8 worth?
The government has obligated $19,332 on SPE2DR26FCZG8.
Is contract SPE2DR26FCZG8 an order under another contract?
Yes. SPE2DR26FCZG8 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZG8 competed?
The extent of competition for SPE2DR26FCZG8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award